anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/OBJECTIVES: We have previously described that low adherence to the Mediterranean diet (MD) in elderly patients admitted in internal medicine wards is linked to poorer clinical outcomes. This investigation was designed to explore whether adherence to the MD is related to circulating markers of redox balance and inflammation in this clinical scenario.
METHODS: A cross-sectional study was performed on 306 acute old patients hospitalized in internal medicine wards. Adherence to the MD was estimated by the Italian Mediterranean Index (IMI). The circulating markers of redox balance were assessed in serum and erythrocytes and correlated with inflammatory markers across different MD adherence groups.
RESULTS: Compared to the patients with high adherence, those with low adherence to the MD exhibited severely impaired redox balance, as evidenced by a higher GSSG/GSH ratio and increased serum hydroxynonenal/malondialdehyde-protein adducts. No modifications were described in the expression of antioxidant enzymes in peripheral blood mononuclear cells. Patients with low adherence to the MD exhibited a higher neutrophil-to-lymphocyte ratio and markers of systemic inflammation, as well as raised levels of interleukin-6 and tumor necrosis factor, compared to those with high MD adherence. A strong association was observed between the circulating markers of redox balance and inflammation/immune response, with the highest regression coefficients found in the low adherence group.
CONCLUSIONS: Old patients admitted to internal medicine wards with low adherence to the MD display unfavorable profiles of the circulating markers of redox balance and inflammation. It is conceivable that such effects on redox balance can be linked to the high polyphenol content of MD. This study supports the rationale for intervention trials that attest to the effectiveness of MD as a nutritional strategy for disease prevention.
Sleep is crucial for health and development. Evidence indicates that sleep changes over time and distinct subgroups may experience different longitudinal patterns. This study systematically reviewed the studies that used latent trajectory modeling to investigate sleep trajectories of children and adolescents aged 0-18 years, and summarized the associated determinants and health-related outcomes. We searched PubMed, Embase, CENTRAL, PsycINFO, and Web of Science, identifying 46 articles that met our criteria. To ensure the reliability of the review, only studies rated as good or fair in terms of methodological quality were included, resulting in a total of 36 articles. Group-based trajectories were identified on several sleep dimensions (i.e., sleep duration, general and specific sleep problems, and bed-sharing behavior) and three or four trajectories were reported in most studies. There was a convergence trend across sleep duration trajectories during the first six years of life. Studies on specific sleep problem (i.e., insomnia, night-waking, and sleep-onset difficulties) typically identified two trajectories: consistent, minimal symptoms or chronic yet fluctuating symptoms. Lower socioeconomic status, maternal depression, and night feeding behaviors were the most frequently reported determinants of sleep trajectories. Membership in a group with certain adverse patterns (e.g., persistent short sleep duration) was associated with increased risks of multiple negative health-related conditions, such as obesity, compromised immunity, neurological problems, substance use, or internalizing/externalizing symptoms. Generally, there is potential to improve the quality of studies in this field. Causality is hard to be inferred within the current body of literature. Future studies could emphasize early life sleep, incorporate more assessment timepoints, use objective measures, and employ experimental design to better understand changes of and mechanisms behind the various sleep trajectories and guide targeted interventions for at-risk subpopulations.
<P>PROBLEM TO BE SOLVED: To provide an oily liquid polyphenol preparation containing polyphenols at the highest possible concentration, essentially free from the third components such as surfactants, having excellent preservation stability and, accordingly, useful in various fields such as foods, drinks, cosmetics and medicines and their production raw materials, and to provide a method for producing the preparation.  <P>SOLUTION: The polyphenol preparation having excellent preservation stability contains polyphenols dissolved in a fatty acid triglyceride at high concentration and is essentially free from the third components other than polyphenols. The method for producing the polyphenol preparation comprises mixing of polyphenols with a fatty acid triglyceride at a mixing ratio of 1-100 pts.wt. of the fatty acid triglyceride based on 1 pt.wt. of the polyphenols, causing contact of the obtained mixture in a slurry state essentially in the absence of the third components, and performing solid-liquid separation of the obtained mixture.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE:To obtain the subject red blood cell-hematopoietics useful for improvement of an anemia state especially during application of a chemotherapeutic agent in a cancer-carrying state by using an immunostimulant in combination with erythropoietin. CONSTITUTION:An objective drug is obtained by using an immunostimulant, e.g. lenthinan, picibanil and kurestin, especially lenthinan belonging to neutral polysaccharide, having no direct toxicity to cells and excellent in an activation effect on biophylaxis function in combination with erythropoietin(EPO). The immunostimulant remarkably increases EPO-sensitive precursor cells for red blood cell-hematopoiesis and the anemia state is improved by an effect of EPO on the above-mentioned precursor cells. As the dosage form, a simple drug form containing both the components is recommendably used and separate administration of both the components is also recommendable. A parenteral drug, especially an injection composed of an isotonic aqueous solution or suspension is suitable in general.
The workflow that is automated by the PSST for Sepsis solution is tightly integrated with Registration, Bedside Monitoring Equipment (BME), and Lab data. As patients arrive in the unit, workflow activities are started with patient context. Typical implementations of the IHI guidelines for Sepsis screening dictate that patients are rescreened on regular intervals to detect Sepsis. The PSST for Sepsis solution will monitor Lab and BME data stores and continually update the screening forms for a particular patient. It will also alert clinicians when a manual screen is required in the Microsoft InfoPath form. The constant screening loop is managed by the PSST for Sepsis solution and will continue to run until the patient screens positive for Severe Sepsis, or moves to the next workflow of auditing a patient with Sever Sepsis.

When patients reach a state of "positive screen" (either manually, or through the automated data monitors) the PSST for Sepsis solution will move this patient from a screening workflow to an auditing workflow automatically. The PSST for Sepsis solution will then monitor the treatment process through Microsoft InfoPath form posts and alert clinicians when treatment goals have not been met. After a successful auditing process and completion of the 6 and 24 hour bundles, the patient will be placed back into a screening workflow. The end result is that patients will remain in a screening/auditing workflow loop until the patient is discharged from the unit.
Two double-blinded, placebo-controlled studies of similar design were conducted in patients with IBS-C. IBS was defined as abdominal pain or discomfort occurring over at least 6 months with two or more of the following: 1) relieved with defecation; 2) onset associated with a change in stool frequency; and 3) onset associated with a change in stool form. Patients were sub-typed as having IBS-C if they also experienced two of three of the following: 1) < 3 spontaneous bowel movements (SBMs) per week, 2) > 25% hard stools, and 3) > 25% SBMs associated with straining.

Following a 4-week baseline/washout period, a total of 1154 patients (mean age 46.6 [range 18–85] years; 91.6% female; 77.4% Caucasian, 13.2% African American, 8.5% Hispanic, 0.4% Asian; 8.3% ≥ 65 years of age) were randomized and received Amitiza 8 mcg twice daily (16 mcg/day) or placebo twice daily for 12 weeks. The primary efficacy endpoint was assessed weekly utilizing the patient's response to a global symptom relief question based on a 7-point, balanced scale ("significantly worse" to "significantly relieved"): "How would you rate your relief of IBS symptoms (abdominal discomfort/pain, bowel habits, and other IBS symptoms) over the past week compared to how you felt before you entered the study?"

The primary efficacy analysis was a comparison of the proportion of "overall responders" in each arm. A patient was considered an "overall responder" if the criteria for being designated a "monthly responder" were met in at least 2 of the 3 months on study. A "monthly responder" was defined as a patient who had reported "significantly relieved" for at least 2 weeks of the month or at least "moderately relieved" in all 4 weeks of that month. During each monthly evaluation period, patients reporting "moderately worse" or "significantly worse" relief, an increase in rescue medication use, or those who discontinued due to lack of efficacy, were deemed non-responders.

The percentage of patients in Study 1 qualifying as an "overall responder" was 13.8% in the group receiving Amitiza 8 mcg twice daily compared to 7.8% of patients receiving placebo twice daily. In Study 2, 12.1% of patients in the Amitiza 8 mcg group were "overall responders" versus 5.7% of patients in the placebo group. In both studies, the treatment differences between the placebo and Amitiza groups were statistically significant.

The two randomized, placebo-controlled, double-blinded studies comprised 97 (8.4%) male patients, which is insufficient to determine whether men with IBS-C respond differently to Amitiza from women. Results in men:

During a 4-week randomized withdrawal period following Study 1, patients who received Amitiza during the 12-week treatment period were re-randomized to receive either placebo or to continue treatment with Amitiza. In Amitiza-treated patients who were “overall responders” during Study 1 and who were re-randomized to placebo, SBM frequency rates did not result in worsening compared to baseline.
Patients with osteoarthritis of knee. They are going to received HA injection 1 vial per week for 5 weeks.
Oppositional defiant disorder (ODD) and conduct disorder (CD) are two common childhood psychiatric disorders. Children with ODD frequently have temper tantrums, argue excessively with adults, deliberately attempt to annoy or upset people, and blame others for their mistakes or behavior. Children with CD may exhibit aggression toward people and animals, destruction of property, deceitfulness, and rule breaking. The symptoms of these disorders can negatively affect children's social, family, and academic lives. Research has shown that early, comprehensive treatment leads to better treatment outcomes. Both disorders are commonly treated using parent training techniques. A multiple family group therapy setting may prove to be more engaging and beneficial than standard care for both parents and children. This study will examine the effectiveness of a multiple family group (MFG) mental health service delivery strategy in improving mental health service use and treatment outcome for urban, low income children of color with ODD or CD.

Participants in this 18-month, open-label study will be randomly assigned to either receive standard of care or participate in an MFG in addition to receiving standard of care. Participants assigned to standard of care will receive treatment that is traditionally offered to outpatients. Participants in an MFG will meet in their groups once a week for 16 weeks. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment. Assessments of youth functioning will be held at Weeks 8 and 16 and Months 6 and 18 post-treatment.
The invention discloses a duck gamma interferon mutant and a preparation method and application thereof. The invention determines that the sequence shown in SEQ ID NO.1 is the original amino acid sequence of duck gamma interferon, and performs signal peptide site mutation on the duck gamma interferon to obtain the mutant shown in SEQ ID NO. 3. The invention further carries out codon optimization on the gene sequence of the mutant to obtain the optimized gene shown as SEQ ID No.6 with obviously improved expression efficiency in the silkworm. The invention carries out amino acid single site mutation and multi-site mutation on the basis of the mutant sequence to obtain a plurality of duck gamma interferon mutants with improved antiviral activity. The duck gamma interferon mutant is further expressed in a silkworm bioreactor by using a silkworm baculovirus expression system, the antiviral activity of the duck gamma interferon mutant is greatly improved, the duck gamma interferon mutant can be used for preventing or treating duck viral diseases, and has remarkable defense and inhibition effects on viral infectious diseases which have great threat in the duck breeding industry.
Dose escalation will follow a modified (3+3) design to establish the preliminary RP2D and characterize the safety and pharmacokinetic profile of PTM-101, which will be taken together with all prior clinical data to establish and characterize the preliminary RP2D. A maximum of 12 subjects with treatment-naïve, borderline resectable or locally advanced PDAC will be recruited and receive PTM-101 combined with standard of care neoadjuvant chemotherapy, and be followed for a minimum of 24 months.
Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
An anhydrous composition comprising oxyresveratrol and butylene glycol in a cosmetically or pharmaceutically acceptable medium. Preferably the composition comprises solely oxyresveratrol and butylene glycol. The composition may comprise additional anhydrous solvents. Also disclosed is a cosmetically or pharmaceutically acceptable formulation comprising at least first and second parts, the first part comprising the anhydrous composition and the second part comprising one or more anhydrous or aqueous solvents. The formulation may comprise preservatives, skin conditioning agents, stabilisers, antioxidants or sulphur dioxide donors. Preferably the skin conditioning agent is gluconolactone and the sulphur dioxide donor is sodium metabisulphite. The anhydrous composition or formulation may also comprise additional components to lighten the skin. Also disclosed are a method of preparing a ready-to-use cosmetically or pharmaceutically acceptable mixed formulation for lightening skin. A kit is also disclosed comprising a first supply of the first part of the formulation, and at least a second supply of the second part of the formulation. The first and/or second parts of the formulation may be impregnated onto a solid, preferably cloth, tissue or sponge. Also disclosed is the use of the composition or formulation for skin lightening, preferably in conjunction with a microneedle roller.
S. aureus is one of the first isolated pathogens recovered from the airways of CF patients. In many patients, S. aureus persists for decades in spite of antibiotic treatment and host defence. During persistence in the airways, S. aureus needs to adapt to this hostile niche. Just recently, the investigators described mucoid S. aureus isolates as a so far not reported phenotype recovered from the airways of CF patients. These mucoid isolates carried a 5bp-deletion in a part of the "intercellular adhesion operon (ica) leading to hyper-expression of biofilm. So far, neither the prevalence of mucoid S. aureus nor the impact on lung disease in CF patients is known. The investigators plan to perform a clinical study to determine the prevalence of mucoid S. aureus isolates in a cross-sectional study and the impact of identified mucoid S. aureus on the clinical course of the lung disease by observing patients with mucoid S. aureus for 12 months in comparison with a group of age-, gender- and P. aeruginosa-positive/negative matched group of S. aureus-positive patients without mucoid isolates.
A technique for workload processing includes receiving a request to process a workload by a scheduler. A determination is made whether multiple stages of processing are needed to process data of the workload. If so, a determination is made of a process needed for each stage and historical processing data is accessed to determine historical execution statistics associated with previous processing requests for a corresponding type of the workload. At each stage, a determination is made whether the data of the workload is available for processing and, if so, whether the respective process of the workload is available. If available, a determination is made as to resource availability on a computing platform for processing the workload and whether the resources available are sufficient to process the workload based on the historical execution statistics. If sufficient resources are available, processing of the workload is initiated for the respective stage.
PURPOSE: A composition containing a methanol extract of the ginseng rhizome and a butanol fraction thereof as an effective ingredient is provided. The composition shows activity against gastritis and ulcer without side effects and thus can be used as an antigastritis and/or antiulcer agent or a functional food. CONSTITUTION: The ginseng rhizome is ground, extracted in methanol or a mixed solvent of methanol and water and then concentrated under reduced pressure to obtain a methanol extract. Thereafter, the methanol extract is dissolved in a mixed solvent of methanol, water and hexane to separate into a hexane layer and an aqueous layer, chloroform is added to the aqueous layer to obtain an aqueous layer. Then, butanol is added to the aqueous layer to obtain a butanol layer, which is concentrated under reduced pressure and dried. The effective dosage of the butanol fraction thereof is 1 to 150mg/kg and LD50 is 5,000mg/kg.
At present there is no data available to describe the impact of musculoskeletal (MSK) disease on the Quality of life and General Health for patients attending Rheumatology MSK triage clinics in SUH and OHLM or in similar service around Ireland. A new questionnaire (MSK HQ) has been developed which has been validated in use with this population. This will be completed by the patient on the day of the appointment and again a year later. Their number of visits to secondary care in the year after their visit will also be captured and analysed. This information will inform the health service of the outcomes of these patients and the impact of their MSK disease on the health service. It will also help with resource allocation and planning for future services, which will ensure the best service for these patients in the future.

Alongside this, Patient satisfaction and feedback is vital to ensuring service quality and quality improvement. The VSQ 9 will be used to measure Patient Satisfaction in this study to evaluate if patients are satisfied with the service they have received on the day. The repeated MSK HQ will help identify if their triage clinic appointment was beneficial to their Quality of life.
Patient in supine position, the therapist performs pressure with first and second finger in PGM marked previously, this is performed until the patient tolerance, when the patient refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier. Repeat the process for 90 seconds.
This disclosure describes a system for performing multinational clinical trials and data collection for each trial. In some embodiments, the data collected will be collected in the current language for each specific user. In some embodiments, data collected from each country can be collected in separate categories or in different ways. In some embodiments, a form is presented in a language that is dependent on the geolocation of a computer accessing the form. For example, forms accessed in the United States will appear in English, data collected in Mexico will appear in Spanish, etc. In some embodiments, a user can enable the data collection form to be presented in multiple languages. In some embodiments, the user can translate the form and input text into different languages, and into multiple languages simultaneously.
During each treatment phase, subjects will receive celecoxib (100 mg by mouth twice daily), naproxen (250 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
This randomized-controlled pilot study uses a wait-list control design. A wait-list design includes a control group that is assigned to a waiting list to receive an intervention after the active treatment group does. In this study, the active group will receive the psilocybin at weeks 5 and 9 and the wait-list control group will receive psilocybin at weeks 30 and 34. The wait-list control group serves the purpose of providing an untreated comparison for the active treatment group, while at the same time allowing the wait-list participants an opportunity to obtain the intervention at a later date.

This study's procedures include screening, preparatory meetings, psilocybin sessions, and follow-up assessments. A large battery of behavioral and psychological measures will be assessed throughout. The study team will consent and enroll up to 86 subjects to obtain a total of 12 completer participants as well as 2-3 family members or friends per study participant who can assess said completers on the Observer Rating Form (COM-R). This number will account for screen-failures and dropouts as well. The 12 participants will be randomly assigned to either an immediate participation group (N=6) or a 6-month delayed participation group (N=6). Although statistical power calculations show that 12 participants will be sufficient to detect the major effects anticipated in this study, the sponsor of this study (The Council on Spiritual Practices) is concurrently funding Johns Hopkins University School of Medicine to conduct a methodologically identical study with 12 additional participants (IND #59009). This will permit the two sites to collaborate post study completion and combine the data from the two studies to provide statistical power to detect even more subtle effects of the psilocybin intervention. Twelve volunteers (6 from each group) will participate at Johns Hopkins and 12 at New York University. Randomization and data analysis will be conducted at New York University.